{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:53:11Z","timestamp":1788576791619,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41433-021-01396-2","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T18:21:25Z","timestamp":1611598885000},"page":"3266-3276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Macular neovascularization in AMD, CSC and best vitelliform macular dystrophy: quantitative OCTA detects distinct clinical entities"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-8414","authenticated-orcid":false,"given":"Alessandro","family":"Arrigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bordato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Aragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Battaglia Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0161-6420(86)33609-1","volume":"93","author":"WR Green","year":"1986","unstructured":"Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology. 1986;93:1169\u201376.","journal-title":"Ophthalmology"},{"key":"1396_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1167\/iovs.18-24624","volume":"59","author":"R Patel","year":"2018","unstructured":"Patel R, Wang J, Campbell JP, Kiang L, Lauer A, Flaxel C, et al. Classification of choroidal neovascularization using projection-resolved optical coherence tomographic angiography. Invest Ophthalmol Vis Sci. 2018;59:4285\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1396_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ajo.2018.08.001","volume":"195","author":"A Arrigo","year":"2018","unstructured":"Arrigo A, Aragona E, Capone L, Pierro L, Romano F, Bandello F, et al. Advanced optical coherence tomography angiography analysis of age-related macular degeneration complicated by onset of unilateral choroidal neovascularization. Am J Ophthalmol. 2018;195:233\u201342.","journal-title":"Am J Ophthalmol"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1097\/IAE.0000000000002775","volume":"40","author":"A Arrigo","year":"2020","unstructured":"Arrigo A, Romano F, Aragona E, Di Nunzio C, Battista M, Bandello F, et al. Optical coherence tomography angiography can categorize different subgroups of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2020;40:2263\u201369.","journal-title":"Retina"},{"key":"1396_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1167\/tvst.9.9.48","volume":"9","author":"A Arrigo","year":"2020","unstructured":"Arrigo A, Aragona E, Di Nunzio C, Bandello F, Parodi MB. Quantitative optical coherence tomography angiography parameters in type 1 macular neovascularization secondary to age-related macular degeneration. Transl Vis Sci Technol. 2020;9:48.","journal-title":"Transl Vis Sci Technol"},{"key":"1396_CR7","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606\u201317.","journal-title":"N Engl J Med"},{"key":"1396_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40406-y","volume":"9","author":"GI Lee","year":"2019","unstructured":"Lee GI, Kim AY, Kang SW, Cho SC, Park KH, Kim SJ, et al. Risk factors and outcomes of choroidal neovascularization secondary to central serous chorioretinopathy. Sci Rep. 2019;9:3927.","journal-title":"Sci Rep"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/IAE.0000000000001357","volume":"37","author":"KN Khan","year":"2017","unstructured":"Khan KN, Mahroo OA, Islam F, Webster AR, Moore AT, Michaelides M. Functional and anatomical outcomes of choroidal neovascularization complicating BEST1-related retinopathy. Retina. 2017;37:1360\u201370.","journal-title":"Retina"},{"key":"1396_CR10","first-page":"CD005139","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3:CD005139.","journal-title":"Cochrane Database Syst Rev"},{"key":"1396_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/IAE.0000000000000804","volume":"36","author":"J Chhablani","year":"2016","unstructured":"Chhablani J, Pichi F, Silva R, Casella AM, Murthy H, Banker A, et al. Antiangiogenics in choroidal neovascularization associated with laser in central serous chorioretinopathy. Retina. 2016;36:901\u20138.","journal-title":"Retina"},{"key":"1396_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/eye.2015.208","volume":"30","author":"HQ Lu","year":"2016","unstructured":"Lu HQ, Wang EQ, Zhang T, Chen YX. Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond). 2016;30:15\u201322.","journal-title":"Eye (Lond)"},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82\u2013118.","journal-title":"Prog Retin Eye Res"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00417-017-3888-2","volume":"256","author":"W Fan","year":"2018","unstructured":"Fan W, Abdelfattah NS, Uji A, Lei J, Ip M, Sadda SR, et al. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol. 2018;256:511\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01396-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T13:08:18Z","timestamp":1658322498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01396-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01396-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FB is a consultant for Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (\u00c9vry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}